SHR 3680Alternative Names: SHR3680
Latest Information Update: 04 Oct 2016
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Androgen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 01 Sep 2016 Phase-I clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Monotherapy) in Australia (PO) (NCT02747342)
- 20 Apr 2016 Jiangsu HengRui Medicine plans a phase I trial for Prostate cancer (Second-line therapy or greater, Metastatic disease, Castration-resistant) in Australia (PO) (NCT02747342)
- 01 Apr 2016 Phase-I/II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease) in China (PO) (NCT02691975)